| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00549757 2007-000860-25 Details | 2014-04-21 Interventional | 3 | 8606 | Aliskiren Cardiovascular … Diabetes Mellit… Diabetes Mellit… Cardiovascular … Type 2 Diabetes… | Lack of benefit and safety concern - | |||
| NCT00086684 NCT00399139 Details | 2014-04-21 Interventional | 4 | 369 | Pentosan Sulfur… Cystitis Cystitis, Inter… Interstitial Cy… | Interim Analysis showed that study continuation was futile. No safety concerns were raised
during the trial. - | |||
| NCT00215943 Details | 2014-04-17 Interventional | 3 | 90 | Dexamethasone Doxorubicin Liposomal doxor… Thalidomide Vincristine Zoledronic Acid Multiple Myelom… | Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more
effective regimens. Target accrual for planned analysis (176) was not met. Principal Investigator (PI) determined study must close due to changes in the management of newly diagnosed myeloma (emergence of new drugs, more effective regimens). | |||
| NCT00920309 Details | 2014-04-14 Interventional | 2/3 | 21 | Sirolimus Arthrogryposis Kidney Diseases Polycystic Kidn… Polycystic Kidn… Autosomal Domin… | This study was stopped after larger studies published in the NEJM failed to show a benefit in
treating ADPKD - | |||
| NCT02026947 2013-000458-23 Details | 2014-04-10 Interventional | 2 | 0 | Sodium Benzoate Mental Disorder… Psychotic Disor… Attenuated or T… | We did not commence the trial because there were no patients who could fulfill the inclusion
criteria. - | |||
| NCT01810731 Details | 2014-04-10 Interventional | 2/3 | 0 | Vaccines Influenza, Huma… Malaria HIV Polio Tetanus | Scientific review positive from 3 manufacturers; internal committees did not support due to
deploying new flu vaccines in HIV+ pregnant women in Kenya. - | |||
| NCT01239992 2010-019954-42 Details | 2014-04-10 Interventional | 4 | 12 | Niacin Dyslipidemias Hyperlipidemias Hyperlipoprotei… Metabolic Syndr… Hyperlipoprotei… | negative endpoint study resulting in withdrawal of study drug - | |||
| NCT01216241 Details | 2014-04-10 Interventional | 3 | 36 | Daptomycin Febrile Neutrop… Neutropenia | The study has shown futility and the objectives could not be reached without enrolling a very
large number of subjects. It was felt that this study had shown futility and objectives could not be reached without enrolling a very large number of subjects in a reasonable time frame. | |||
| NCT01725256 Details | 2014-04-09 Interventional | 2 | 29 | Pharmaceutical … Familial Primar… Hypertension Pulmonary Arter… | Terminated early dt to acquisition of Sponsor and change in corporate priorities - | |||
| NCT00678015 Details | 2014-04-09 Interventional | 2 | [1 Refs] | 12 | Masoprocol Prostatic Neopl… Prostate Cancer | Per protocol - interim analysis showed no significant PSA declines among the first 12 patients
after 3 cycles of treatment Per protocol - accrual was stopped early after a pre-planned interim analysis showed no significant PSA declines after 3 cycles of treatment among the first 12 patients enrolled. | ||
| NCT01259297 2009-010170-38 Details | 2014-04-08 Interventional | 3 | 2336 | Aliskiren Amlodipine Hydrochlorothia… Cardiovascular … | Terminated early in agreement with Health Authorities for feasibility reasons Due to early termination, 1759 patients were randomized as against 11,000. Only 25 primary endpoints had accrued during median follow-up of 209 days as against planned 2000 in 5 years. These low numbers significantly limit interpretation of results. | |||
| NCT01199367 Details | 2014-04-07 Interventional | 1 | [1 Refs] | 11 | Lapatinib Letrozole Breast Neoplasm… Breast Cancer | The results of the dose escalation phase did not identify a well-tolerated dose that would
permit further study in Phase 2. - | ||
| NCT01198054 Details | 2014-04-07 Interventional | 4 | 4 | Lenalidomide Leukemia, Myelo… AML | - - | |||
| NCT01193400 2010-019718-25 Details | 2014-04-07 Interventional | 2 | - | Clofarabine Cytarabine Leukemia, Myelo… Leukemia, Myelo… Acute Myelogeno… | - - | |||
| NCT01124097 2010-019101-42 Details | 2014-04-07 Interventional | 3 | 240 | Eslicarbazepine… Neuralgia Neuralgia, Post… Post Herpetic N… | - - | |||
| NCT00495547 2007-000972-18 Details | 2014-04-07 Interventional | 2 | 16 | Azacitidine Epoetin Alfa Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | - - | |||
| NCT00428129 Details | 2014-04-07 Interventional | 2 | 6 | Plasminogen Thrombosis Venous Thrombos… Deep Vein Throm… | Sponsor's decision to not pursue uPLi for vascular conditions including DVT. - | |||
| NCT00123292 Details | 2014-04-07 Interventional | 2 | 19 | Fibrinolysin Plasminogen Arterial Occlus… | Sponsor's decision not to pursue development of uPLi for vascular conditions - | |||
| NCT00123266 Details | 2014-04-07 Interventional | 2 | 2 | Plasminogen Arterial Occlus… Stroke | Sponsor's decision not to pursue development of uPLi for vascular conditions. - | |||
| NCT01578785 2011-005550-57 Details | 2014-04-02 Interventional | 3 | 178 | (T,G)-A-L Glatiramer Acet… Multiple Sclero… Multiple Sclero… Sclerosis Relapsing-Remit… | - - |